GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chemomab Therapeutics Ltd (STU:2QV0) » Definitions » Net Policyholder Benefits/Claims

Chemomab Therapeutics (STU:2QV0) Net Policyholder Benefits/Claims


View and export this data going back to 2021. Start your Free Trial

What is Chemomab Therapeutics Net Policyholder Benefits/Claims?

Net Policyholder Benefits/Claims only applies to insurance companies.


Chemomab Therapeutics Business Description

Traded in Other Exchanges
Address
Kiryat Atidim, Building 7, Tel Aviv, ISR, 6158002
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.